Literature DB >> 90058

Combined functional and immunochemical analysis of normal and abnormal human factor X.

D S Fair, E F Plow, T S Edgington.   

Abstract

Human Factor X was isolated from Cohn fraction III and characterized by polyacrylamide gel electrophoresis, amino acid composition, and isoelectric focusing. Two molecular forms with biological activity were observed at isoelectric points of 4.8 and 5.0. Antisera generated to Factor X was monospecific and used to establish an equilibrium competitive inhibition radioimmunoassay. This assay was specific for human Factor X and did not cross-react with human prothrombin or bovine Factor X within the sensitivity range of 6-300 ng Factor X antigen/ml. The mean concentration of Factor X based on the antigen was 11.9 mug/ml, whereas concentration values based on coagulant activity was 7.8 mug/ml. This 30% difference in measurement appears to result from the presence of a subpopulation of Factor X molecules devoid of coagulant activity. The radioimmunoassay was used to qualitatively and quantitatively compare purified Factor X to plasmic Factor X obtained from normal, warfarintreated, acquired Factor X-deficient, and congenitaldeficient patients. In all but one case, the Factor X present in these plasmas was immunochemically identical to the purified Factor X and permitted precise quantitation of these abnormal Factor X molecules. Factor X procoagulant activity was analyzed relative to Factor X antigen and the specific activities were used to characterize normal and abnormal Factor X molecules. Reduced Factor X activity in plasmas from warfarin-treated and acquired Factor X-deficient patients was attributed to both decreases in Factor X antigen and decreased function of the Factor X molecules. Congenitally deficient patients, in general, showed a reduction in Factor X antigen in parallel with Factor X procoagulant activities resulting from comparable decreases in specific biological activity of the molecules.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 90058      PMCID: PMC372196          DOI: 10.1172/JCI109554

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Factor-VIII-related antigen: multiple molecular forms in human plasma.

Authors:  T S Zimmerman; J Roberts; T S Edgington
Journal:  Proc Natl Acad Sci U S A       Date:  1975-12       Impact factor: 11.205

2.  Immunoradiometric assay of factor VIII related antigen, with observations in 32 patients with von Willebrand's disease.

Authors:  Z M Ruggeri; P M Mannucci; S L Jeffcoate; G I Ingram
Journal:  Br J Haematol       Date:  1976-06       Impact factor: 6.998

3.  DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.

Authors:  B J DAVIS
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

4.  The Stuart-Prower factor assay and its clinical significance.

Authors:  F BACHMANN; F DUCKERT; F KOLLER
Journal:  Thromb Diath Haemorrh       Date:  1958-05-01

5.  Stuart clotting defect. II. Genetic aspects of a new hemorrhagic state.

Authors:  J B GRAHAM; E M BARROW; C HOUGIE
Journal:  J Clin Invest       Date:  1957-03       Impact factor: 14.808

6.  Purification and activation of human factor X: cooperative effect of Ca++ on the activation reaction.

Authors:  D P Kosow
Journal:  Thromb Res       Date:  1976-12       Impact factor: 3.944

7.  The use of Coomassie Brilliant Blue G250 perchloric acid solution for staining in electrophoresis and isoelectric focusing on polyacrylamide gels.

Authors:  A H Reisner; P Nemes; C Bucholtz
Journal:  Anal Biochem       Date:  1975-04       Impact factor: 3.365

Review 8.  Recent developments in understanding the mechanism of vitamin K and vitamin K-antagonist drug action and the consequences of vitamin K action in blood coagulation.

Authors:  C M Jackson; J W Suttie
Journal:  Prog Hematol       Date:  1977

9.  Neoantigenic expressions engendered by plasmin cleavage of fibrinogen.

Authors:  E F Plow; C Hougie; T S Edgington
Journal:  J Immunol       Date:  1971-11       Impact factor: 5.422

Review 10.  Prothrombin structure, activation, and biosynthesis.

Authors:  J W Suttie; C M Jackson
Journal:  Physiol Rev       Date:  1977-01       Impact factor: 37.312

View more
  18 in total

1.  Influence of mutations in tissue factor on the fine specificity of macromolecular substrate activation.

Authors:  S Dittmar; W Ruf; T S Edgington
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

2.  Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome.

Authors:  S Idell; K K James; E G Levin; B S Schwartz; N Manchanda; R J Maunder; T R Martin; J McLarty; D S Fair
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

3.  Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage.

Authors:  S Idell; J Peters; K K James; D S Fair; J J Coalson
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

4.  Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade.

Authors:  D C Altieri; J H Morrissey; T S Edgington
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

5.  Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa.

Authors:  C D Dickinson; C R Kelly; W Ruf
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

6.  Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro: two procoagulant activities are produced by peripheral blood mononuclear cells.

Authors:  B S Schwartz; G A Levy; L K Curtiss; D S Fair; T S Edgington
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

7.  Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition.

Authors:  S Idell; K K James; C Gillies; D S Fair; R S Thrall
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

8.  Factor XSanto Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion.

Authors:  H H Watzke; A Wallmark; N Hamaguchi; P Giardina; D W Stafford; K A High
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

9.  Human alveolar macrophages synthesize factor VII in vitro. Possible role in interstitial lung disease.

Authors:  H A Chapman; C L Allen; O L Stone; D S Fair
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

10.  Lymphoid procoagulant response to bacterial endotoxin in the rat.

Authors:  P A Lando; T S Edgington
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.